Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Drug

Yipinhong Pharmacy’s AR882 Earns FDA Fast-Track Status for Gout Treatment

Fineline Cube Aug 20, 2024

BEIJING—China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced that its novel drug AR882 has...

Company Deals

Sichuan Kelun Pharmaceutical’s H1 2024 Report Highlights MSD Collaboration Milestones

Fineline Cube Aug 20, 2024

CHENGDU—Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has released its financial report for the first...

Policy / Regulatory

NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System

Fineline Cube Aug 20, 2024

BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the...

Company Drug

Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment

Fineline Cube Aug 20, 2024

TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...

Company Drug

BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment

Fineline Cube Aug 20, 2024

FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...

Company Deals

Jiangsu Hengrui Pharmaceuticals Expands R&D Footprint with Jinan Innovation Zone Partnership

Fineline Cube Aug 20, 2024

JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with...

Company Medical Device

China’s NMPA Grants Medical Device License to DaAn Gene’s Monkeypox Detection Kit

Fineline Cube Aug 20, 2024

GUANGZHOU—DaAn Gene Co., Ltd, a subsidiary of Sun Yat-sen University based in China (SHE: 002030),...

Company Deals

Genesis MedTech’s J-VALVE System Transfers to Edwards Lifesciences, Marking a New Era in Aortic Valve Treatment

Fineline Cube Aug 20, 2024

SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards...

Company Drug

Changchun High & New Technology Secures NMPA Approval for Turner Syndrome Treatment

Fineline Cube Aug 20, 2024

CHANGCHUN—Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading biopharmaceutical company in...

Company Drug

AstraZeneca’s Fasenra Secures NMPA Approval for Severe Eosinophilic Asthma Maintenance Therapy

Fineline Cube Aug 20, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has granted market approval for AstraZeneca (NASDAQ:...

Company Drug

Genmab’s Tepkinly/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments

Fineline Cube Aug 20, 2024

COPENHAGEN—Genmab A/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC)...

Company Deals

Multitude Therapeutics and Adcendo ApS Partner on Anti-TF ADC, Targeting Global Cancer Treatment

Fineline Cube Aug 20, 2024

SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics...

Company Medical Device

Lepu Medical Secures Approval for RECATCHOR Catheter, Enhancing Cardiovascular Procedures

Fineline Cube Aug 19, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Drug Policy / Regulatory

Beijing Proposes New Regulations to Enhance Pharmaceutical Retail Standards and Services

Fineline Cube Aug 19, 2024

The Beijing Municipal Medical Products Administration has unveiled a draft proposal titled “Guiding Opinions on...

Company Drug

AstraZeneca’s Imfinzi Gains FDA Approval for Neoadjuvant Use in Early-Stage Lung Cancer

Fineline Cube Aug 19, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based pharmaceutical powerhouse, has secured US FDA approval...

Company

RemeGen Reports 75.6% Revenue Surge in H1 2024, Driven by Key Product Sales

Fineline Cube Aug 19, 2024

RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving...

Company Medical Device

Robotrak Secures NMPA License for China’s First Smart Ophthalmic Navigation Laser

Fineline Cube Aug 19, 2024

Robotrak, a Nanjing-based ophthalmic innovation platform, has secured a Category III medical device license from...

Company Drug

Sichuan Biokin Launches Phase III Trial for Bispecific ADC BL-B01D1 in Lung Cancer

Fineline Cube Aug 19, 2024

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has commenced the first patient dosing in a...

Company Drug

Yixintang Partners with Huawei Cloud to Drive Digital Transformation in Pharma Retail

Fineline Cube Aug 19, 2024

Yixintang Pharmaceutical Group Co., Ltd. (SHE: 002727), a prominent pharmaceutical retail chain in China, has...

Company Deals Digital

Ant Group Eyes Acquisition of Leading Internet Healthcare Platform Haodf.com

Fineline Cube Aug 19, 2024

Ant Group, the China-based fintech powerhouse, is reportedly pursuing the acquisition of Haodf.com, one of...

Posts pagination

1 … 249 250 251 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.